Cargando…
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
BACKGROUND: Raltegravir 1200mg (2×600mg tablets) once daily (QD) demonstrated noninferior efficacy and similar safety to raltegravir 400mg twice daily (BID) at week 48 of the ONCEMRK trial. Here, we report the week 96 results from this study. METHODS: ONCEMRK is a phase 3, multicenter, double-blind,...
Autores principales: | Cahn, Pedro, Sax, Paul E., Squires, Kathleen, Molina, Jean-Michel, Ratanasuwan, Winai, Rassool, Mohammed, Bloch, Mark, Xu, Xia, Zhou, Yan, Homony, Brenda, Hepler, Deborah, Teppler, Hedy, Hanna, George J., Nguyen, Bach-Yen, Greaves, Wayne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075877/ https://www.ncbi.nlm.nih.gov/pubmed/29771789 http://dx.doi.org/10.1097/QAI.0000000000001723 |
Ejemplares similares
-
A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
por: Bukkems, Vera E., et al.
Publicado: (2021) -
Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya
por: Owino, Fredrick, et al.
Publicado: (2013) -
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
por: Hall, Nolwenn, et al.
Publicado: (2022) -
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
por: Orkin, Chloe, et al.
Publicado: (2020) -
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
por: Mills, Alexander, et al.
Publicado: (2021)